Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02114528
Other study ID # 20130425
Secondary ID
Status Terminated
Phase Phase 4
First received April 4, 2014
Last updated November 13, 2015
Start date October 2014
Est. completion date November 2015

Study information

Verified date November 2015
Source Ottawa Heart Institute Research Corporation
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether catheter based ablation is better than conventional anti-arrhythmic drug (AAD) therapy for reducing recurrent shocks in patients with an implantable cardioverter defibrillator (ICD). The second purpose of the study is to determine the safety of catheter-based ablation and the effect on quality of life of patients.

The study hypothesis is that catheter ablation is superior to AAD therapy in preventing recurrent ventricular arrhythmia in such subjects. This is a pilot trial which will provide data regarding recruitment potential and the feasibility of conducting a larger trial.


Description:

AAD and catheter ablation have been shown to reduce the incidence of recurrent AICD shocks. The disadvantages of AAD include side effects from medications and the lack of compliance during long-term therapy. Previous trials have demonstrated the feasibility, safety and efficacy of catheter ablation as "first-line" treatment for reducing recurrent ventricular arrhythmia and AICD shocks in this subject population. However, these catheter ablation trials did not systematically compare the efficacy of catheter ablation with AAD therapy. While both treatment strategies have been shown to be effective in this setting it is unclear how they compare with each other in preventing AICD shocks.

This is a single centre, parallel group, two-arm, unblinded randomized vanguard pilot trial comparing catheter ablation with AAD therapy for preventing recurrent AICD shocks.

Eligible and consenting subjects will be equally randomized to receive either AAD therapy or a catheter ablation procedure.

A 30-day treatment period will be provided to allow for adequate time to implement the two treatments.

Subjects randomized to the antiarrhythmic therapy arm will receive clinically effective loading doses of either sotalol, mexiletine, procainamide or amiodarone (oral or IV) alone or in combination, as chosen by the study investigator.

Subjects randomized to the catheter ablation arm will undergo the procedure within the 30 treatment period. Concomitant antiarrhythmic therapy with amiodarone or other AAD will be avoided if possible in the ablation group. However, AAD may be used to suppress ventricular arrhythmia resulting in AICD shocks or anti-tachycardia pacing (ATP) while waiting for the catheter ablation procedure.

Subjects will be seen for a baseline randomization visit, then at 3, 6, 9 and 12 months after enrollment and every 3 months thereafter until the end of the study. Subjects will be followed up for a minimum of 12 months and a maximum of 24 months.

Quality of life questionnaires will be done at each visit. Standard of care blood work, chest x-ray, and ECG will be done in the AAD arm depending on the AAD chosen as treatment. ICD programming will be standardized for all subjects.


Recruitment information / eligibility

Status Terminated
Enrollment 40
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- = 18 and = 85 years old

- Able to provide informed consent

- AICD implanted for primary prophylaxis against sudden cardiac death

- AICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes

- CAD with prior myocardial infarction (>60 days prior to enrollment)

- AICD or ECG documentation of ventricular arrhythmia responsible for appropriate AICD therapy (> 3 ATP or = 1 appropriate Shock)

Exclusion Criteria:

- Contraindication or allergy to contrast media, routine procedural medications or catheter materials

- Contraindication to an interventional procedure

- Current or previous (within 3 months) antiarrhythmic therapy

- Absolute contraindication to amiodarone or other AAD

- New York Heart Association (NYHA) functional class IV

- Stroke within the past 90 days

- Unstable angina

- Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or long QT syndrome

- Subjects with active ischemia that are eligible for revascularization

- Life expectancy less than 6 months

- Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation

- Untreated hypothyroidism or hyperthyroidism. Subjects who are euthyroid on thyroid hormone replacement therapy are acceptable.

- Current enrollment in another investigational drug or device study.

- Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the Subject for the entire study period.

- Absolute contra-indication to the use of heparin and or warfarin.

- Documented intra-atrial thrombus, ventricular thrombus (< 6 months after detection of thrombus), tumor, or another abnormality, which precludes catheter introduction.

- Previous VT ablation

- Are pregnant.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Antiarrhythmic Drug Therapy
Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
Procedure:
Catheter ablation
Ventricular tachycardia catheter ablation.

Locations

Country Name City State
Canada University of Ottawa Heart Institute Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Heart Institute Research Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Appropriate ICD therapy Appropriate AICD therapy after the 30 day treatment period; defined as = 1 appropriate Shock or ATP that needs further intervention in the form of catheter ablation or AAD therapy. After 30 day treatment period Yes
Secondary Composite Safety Endpoint Catheter ablation arm- procedure related complications, need for concomitant use of AAD (sotalol, mexiletine, propafenone or amiodarone) and/or death.
Antiarrhythmic arm- medication side effects, discontinuation of AAD and death, inappropriate shocks from AICD.
Slow VT below AICD tachyarrhythmia detection threshold that leads to hospitalization or necessitates catheter ablation
Mortality
Quality of life score in each treatment arm using the EQ-5D questionnaire
Health care resource utilization
Up to 24 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03453645 - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation NCT02962076 - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia Early Phase 1
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Completed NCT01791543 - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia N/A
Terminated NCT02891863 - Low Energy Therapy to Convert Ventricular Tachycardias Phase 0
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT01294267 - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation N/A
Terminated NCT00383799 - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT04642963 - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia N/A
Recruiting NCT05377216 - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation Early Phase 1
Not yet recruiting NCT04990089 - VIVO European Observational Registry
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting NCT03631303 - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting NCT03611465 - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts N/A